Angiogenesis, the sprouting of new blood vessels from existing vessels, is one of six known
mechanisms employed by solid tumors to recruit blood vessels necessary for their initiation …

Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and
oxygen supply to the tumor cells through the decrease of the vascular network and the …

Tumor growth and metastasis rely on tumor vascular network for the adequate supply of
oxygen and nutrients. Tumor angiogenesis relies on a highly complex program of growth …

Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers.
Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular …

The vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase receptor
for VEGF-A, VEGF-B, and placental growth factor (PlGF) ligands that is expressed in …

Selective inhibition of vascular endothelial growth factor (VEGF) increases the efficacy of
chemotherapy and has beneficial effects on multiple advanced cancers, but response is …

Placental growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF)
family that also comprises VEGF-A (VEGF), VEGF-B, VEGF-C, and VEGF-D. Unlike VEGF …

Angiogenesis research in the past two decades has contributed significantly towards
understanding the molecular pathophysiology of cancer progression and inspired target …

Background Circulating angiogenic factors are altered in patients with mCRC receiving
bevacizumab. Evaluation of alterations in levels of VEGF ligands may provide insights into …

The introduction of agents that inhibit tumor angiogenesis by targeting vascular endothelial
growth factor (VEGF) signaling has made a significant impact on the survival of patients with …